Products with Anticancer bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN4327 | Ursolic acid |
| Ursolic acid is a potential PPARγagonist, which has anti-tumor, chemopreventive, hepatoprotective, anti-inflammatory, antioxidant, antidepressant-like, antimicrobial activities, and anti-asthmatic effects. Ursolic acid also has antihyperlipidemic, hypoglycemic and direct cardiac effect, its antihypertensive effect is attributed to its potent diuretic-natriuretic-saluretic activity. Ursolic acid regulates NF-κB, VEGF, COX-2, Nrf2, ARE, IL-5, IL-13, IL-17and MAPK signaling pathways. | |
| BCN4330 | 19-Hydroxybaccatin III |
| 1. 19-Hydroxybaccatin III, 10-deacetylcephalomannine, and 10-deacetyltaxol are new antitumor taxanes from Taxus wallichiana. | |
| BCN4376 | Stigmasterol |
| Stigmasterol is used as a precursor in the manufacture of synthetic progesterone, it is an antagonist of the bile acid nuclear receptor FXR, which has anti-inflammatory, thyroid inhibitory, cholesterol-lowering, antiperoxidative and hypoglycemic effects; it has indicated that stigmasterol may be useful in prevention of certain cancers, including ovarian, prostate, breast, and colon cancers. Stigmasterol inhibits the NF-kappaB pathway. | |
| BCN4387 | Rocaglamide |
| 1. Rocaglamide induces apoptosis through the intrinsic death pathway in various human leukemia cell lines and in acute lymphoblastic leukemia, chronic myeloid leukemia and acute myeloid leukemia cells freshly isolated from patients. 2. Rocaglamides are potent natural anticancer products that inhibit proliferation of various cancer cells at nanomolar concentrations, it prevents tumor growth and sensitize resistant cancer cells to apoptosis by blocking the MEK-ERK-eIF4 pathway. 3. Rocaglamides can suppress the PMA-induced expression of NF-kappaB target genes and sensitize leukemic T cells to apoptosis induced by TNFalpha, cisplatin, and gamma-irradiation, suggests that rocaglamide derivatives could serve as lead structures in the development of anti-inflammatory and tumoricidal drugs. 4. Rocaglamide and a XIAP inhibitor cooperatively sensitize TRAIL-mediated apoptosis in Hodgkin's lymphomas. | |
| BCN4390 | Eriocalyxin B |
| 1. Eriocalyxin B is a potent NF-kappaB inhibitor, can inhibit the NF-kappaB transcriptional activity but not that of cAMP response element-binding protein. 2. Eriocalyxin B reversibly interfer with the binding of p65 and p50 subunits to the DNA in a noncompetitive manner. 3. Eriocalyxin B exerts potent antiinflammatory effects through selective modulation of pathogenic Th1 and Th17 cells by targeting critical signaling pathways. 4. Eriocalyxin B inhibits proliferation and induces apoptosis through downregulation of Bcl-2 and activation of caspase-3 in human bladder cancer cells. 5. Eriocalyxin B induces apoptosis and cell cycle arrest in pancreatic adenocarcinoma cells through caspase- and p53-dependent pathways, should be considered a candidate for pancreatic cancer treatment. 6. Eriocalyxin B is a specific inhibitor of STAT3, it directly targets STAT3 through a covalent linkage to inhibit the phosphorylation and activation of STAT3 and induces apoptosis of STAT3-dependent tumor cells. | |
